Felix device development update
Filed with ASX · · 23 pages · English
Memphasys (ASX: MEM) reports that development of Felix, the device that MEM is commercialising, is proceeding according to plan. Felix separates the most viable sperm in a semen sample for use in IVF and provides unique and critical advantages over current sperm processing methods. An updated presentation on development of the Felix device is attached. Over the past few months, MEM and the Univers
Earlier from Memphasys
- Appendix 4D - December 2017 Half year Financial Accounts
- Legal action with Platinum Road / Bridge Road Capital
- $400,000 Special Grant received from the NSW Medical Devices
- MEM Non-Renounceable Rights Issue Offer
- $400,000 special grant offer from NSW Medical Devices Fund
Later from Memphasys
- Memphasys raises $1m via a strategic investment
- Proposed share consolidaiton
- Collaborative Agreement with Monash IVF Group
- Pause in trading
- Response to ASX price query
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys